BridgeMD
New treatment option for Solid Tumor
Official title Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
ClinicalTrials.gov ID: NCT06739395
What this study is testing
What is Olaparib tablet?
Olaparib tablet is an investigational medicine, given as an once-daily, being studied as a potential treatment for solid tumor.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The main purpose of this study is to explore the feasibility of selecting treatment plans based on genomic variations guided by MTB in patients with advanced refractory solid tumors.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Recurrent or metastatic malignant solid tumors diagnosed by histology or cytology;
- ECOG score 0-4 (3-4 points only for patients with tumor burden);
- Those who fail or cannot tolerate standard treatment, or those who refuse standard treatment;
- At least one measurable lesion that meets the RECIST 1.1 standard;
- Expected survival period ≥ 3 months;
You likely can't join if
- Patients who have actively undergone or are currently participating in clinical trials for treatment;
- Serious or uncontrolled medical diseases (i.e. uncontrolled diabetes, chronic kidney disease, chronic lung disease or uncontrolled active infection...
- Pregnant or lactating patients, or any patients with fertility, have not taken appropriate pregnancy prevention measures.
See the full eligibility criteria
- Recurrent or metastatic malignant solid tumors diagnosed by histology or cytology;
- ECOG score 0-4 (3-4 points only for patients with tumor burden);
- Those who fail or cannot tolerate standard treatment, or those who refuse standard treatment;
- At least one measurable lesion that meets the RECIST 1.1 standard;
- Expected survival period ≥ 3 months;
- Age ≥ 18 years old;
- Tumor tissue blocks with sufficient formalin fixed paraffin embedding (FFPE), or chest or ascites with cancer cells detected during treatment (not less than 200ml), or excised metastatic lymph nodes, or peripheral blood...
- Understand and voluntarily participate in this study, and sign the informed consent form.
- Patients who have actively undergone or are currently participating in clinical trials for treatment;
- Serious or uncontrolled medical diseases (i.e. uncontrolled diabetes, chronic kidney disease, chronic lung disease or uncontrolled active infection, mental diseases/social conditions that limit the compliance with the...
- Pregnant or lactating patients, or any patients with fertility, have not taken appropriate pregnancy prevention measures.
The study team makes the final eligibility decision.
Where it's taking place
- Tianjin, Tianjin Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tianjin, Tianjin Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.